{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T23:00:44Z","timestamp":1782255644180,"version":"3.54.5"},"reference-count":31,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III (ISCIII)","doi-asserted-by":"publisher","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}]},{"name":"European Union","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}]},{"name":"European Union","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"European Union","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"name":"European Union","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"European Union","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"name":"European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}]},{"name":"European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}]},{"name":"European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"name":"European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"European funds of the Recovery, Transformation and Resilence Plan, and financed by the Instituto de Salud Carlos IIII","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"CIBERONC","doi-asserted-by":"publisher","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","doi-asserted-by":"publisher","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","doi-asserted-by":"publisher","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","doi-asserted-by":"publisher","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","doi-asserted-by":"publisher","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","doi-asserted-by":"publisher","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","doi-asserted-by":"publisher","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cepheid","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}]},{"name":"Cepheid","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}]},{"name":"Cepheid","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"Cepheid","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"name":"Cepheid","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"Cepheid","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","award":["PI22\/01892"],"award-info":[{"award-number":["PI22\/01892"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","award":["CB16\/12\/00316"],"award-info":[{"award-number":["CB16\/12\/00316"]}]},{"name":"European Development Regional Fund \u201cA way to achieve Europe\u201d (FEDER)","award":["CB16\/12\/00295"],"award-info":[{"award-number":["CB16\/12\/00295"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Xpert Breast Cancer STRAT4 is a RT-qPCR platform that studies the mRNA expression of ESR1, PGR, MKI67 and ERBB2, providing a positive or negative result for each of these breast cancer biomarkers. Its concordance with immunohistochemistry (IHC) and in situ hybridization (ISH) has been previously demonstrated, but none of the previous works was focused on HER2-equivocal (2+) cases identified by IHC. Thus, we studied the concordance between IHC\/ISH and STRAT4 results for 112 HER2 2+ IBC samples, using 148 HER2 0+, 1+ and 3+ (no-HER2 2+) samples for comparison. We found 91.3% accuracy for the determination of HER2 status globally, 99.3% for no-HER2 2+ samples and 80.7% for HER2 2+ samples. Regarding the other biomarkers, we obtained 96.4% accuracy for estrogen receptor, 84.1% for progesterone receptor and 58.2% for Ki67. Our results suggest that the use of ERBB2 mRNA for the evaluation of HER2 2+ cases is not a reliable reflex method to assess the ERBB2 amplification status.<\/jats:p>","DOI":"10.3390\/cancers15061688","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T01:31:41Z","timestamp":1678411901000},"page":"1688","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluation of ERBB2 mRNA Expression in HER2-Equivocal (2+) Immunohistochemistry Cases"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1986-2965","authenticated-orcid":false,"given":"Irene","family":"Carretero-Barrio","sequence":"first","affiliation":[{"name":"Servicio de Anatom\u00eda Patol\u00f3gica, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad de Alcal\u00e1, 28801 Alcal\u00e1 de Henares, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"},{"name":"Unidad de Patolog\u00eda Mamaria, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Caniego-Casas","sequence":"additional","affiliation":[{"name":"Servicio de Anatom\u00eda Patol\u00f3gica, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Rosas","sequence":"additional","affiliation":[{"name":"Servicio de Anatom\u00eda Patol\u00f3gica, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Concepci\u00f3n","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Unidad de Patolog\u00eda Mamaria, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"Servicio de Ginecolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelia","family":"Mart\u00ednez-J\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Unidad de Patolog\u00eda Mamaria, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"Servicio de Oncolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Chiva","sequence":"additional","affiliation":[{"name":"Unidad de Patolog\u00eda Mamaria, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"},{"name":"Servicio de Radiolog\u00eda, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Sarri\u00f3","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"},{"name":"Departamento de Bioqu\u00edmica, Universidad Aut\u00f3noma de Madrid (UAM), Instituto de Investigaciones Biom\u00e9dicas \u2018Alberto Sols\u2019, Conexi\u00f3n C\u00e1ncer (UAM-CSIC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5030-6687","authenticated-orcid":false,"given":"Gema","family":"Moreno-Bueno","sequence":"additional","affiliation":[{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"},{"name":"Departamento de Bioqu\u00edmica, Universidad Aut\u00f3noma de Madrid (UAM), Instituto de Investigaciones Biom\u00e9dicas \u2018Alberto Sols\u2019, Conexi\u00f3n C\u00e1ncer (UAM-CSIC), 28029 Madrid, Spain"},{"name":"Fundaci\u00f3n MD Anderson Internacional, 28033 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6730-5066","authenticated-orcid":false,"given":"Jos\u00e9","family":"Palacios","sequence":"additional","affiliation":[{"name":"Servicio de Anatom\u00eda Patol\u00f3gica, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad de Alcal\u00e1, 28801 Alcal\u00e1 de Henares, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"},{"name":"Unidad de Patolog\u00eda Mamaria, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9n","family":"P\u00e9rez-Mies","sequence":"additional","affiliation":[{"name":"Servicio de Anatom\u00eda Patol\u00f3gica, Hospital Universitario Ram\u00f3n y Cajal, Instituto Ram\u00f3n y Cajal de Investigaci\u00f3n Sanitaria (IRYCIS), 28034 Madrid, Spain"},{"name":"Faculty of Medicine, Universidad de Alcal\u00e1, 28801 Alcal\u00e1 de Henares, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"},{"name":"Unidad de Patolog\u00eda Mamaria, Hospital Universitario Ram\u00f3n y Cajal, 28034 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO\/CAP Guideline Update","volume":"38","author":"Allison","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S1470-2045(09)70262-1","article-title":"Ki67 in Breast Cancer: Prognostic and Predictive Potential","volume":"11","author":"Yerushalmi","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000524227","article-title":"Unusual Patterns of HER2 Expression in Breast Cancer: Insights and Perspectives","volume":"89","author":"Grassini","year":"2022","journal-title":"Pathobiology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000132567","article-title":"Immunohistochemical Antibodies in Breast Cancer HER2 Diagnostics","volume":"29","author":"Egervari","year":"2008","journal-title":"Tumor Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-022-03280-0","article-title":"Histologic Analysis According to HER2 Gene Status in HER2 2 + Invasive Breast Cancer: A Study of 280 Cases Comparing ASCO\/CAP 2013 and 2018 Guideline Recommendations","volume":"480","author":"Hwang","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.5858\/arpa.2019-0307-OA","article-title":"Impact of the 2018 American Society of Clinical Oncology\/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2\/CEP17 Ratio <2.0 and Average HER2 Copy Number \u22654.0 and <6.0","volume":"144","author":"Hoda","year":"2019","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/cncr.26406","article-title":"Breast Cancers Presenting Luminal B Subtype Features Show Higher Discordant Human Epidermal Growth Factor Receptor 2 Results between Immunohistochemistry and Fluorescence in Situ Hybridization","volume":"118","author":"Park","year":"2012","journal-title":"Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1200\/JCO.19.01455","article-title":"NSABP B-47\/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+","volume":"38","author":"Fehrenbacher","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","article-title":"HER2-Low Breast Cancers","volume":"157","author":"Zhang","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10549-018-4889-5","article-title":"Comparison of Central Laboratory Assessments of ER, PR, HER2, and Ki67 by IHC\/FISH and the Corresponding MRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-QPCR on an Automated, Broadly Deployed Diagnostic Platform","volume":"172","author":"Wu","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Erber, R., Hartmann, A., Fasching, P.A., Ruebner, M., St\u00f6hr, R., Beckmann, M.W., Zentgraf, M., Popp, V., Weidler, J., and Simon, I. (2021). Reproducibility of MRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancer-A Europe-Wide External Quality Assessment. Cancers, 13.","DOI":"10.3390\/cancers13184718"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Janeva, S., Parris, T.Z., Nasic, S., De Lara, S., Larsson, K., Audisio, R.A., Olofsson Bagge, R., and Kov\u00e1cs, A. (2021). Comparison of Breast Cancer Surrogate Subtyping Using a Closed-System RT-QPCR Breast Cancer Assay and Immunohistochemistry on 100 Core Needle Biopsies with Matching Surgical Specimens. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08171-2"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/ajcp\/aqab016","article-title":"Use of the Xpert Breast Cancer STRAT4 for Biomarker Evaluation in Tissue Processed in a Developing Country","volume":"156","author":"Mugabe","year":"2021","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100228","DOI":"10.1016\/j.esmoop.2021.100228","article-title":"ESR1, PGR, ERBB2, and MKi67 MRNA Expression in Postmenopausal Women with Hormone Receptor-Positive Early Breast Cancer: Results from ABCSG Trial 6","volume":"6","author":"Filipits","year":"2021","journal-title":"ESMO Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/s41374-018-0064-1","article-title":"Macrodissection Prior to Closed System RT-QPCR Is Not Necessary for Estrogen Receptor and HER2 Concordance with IHC\/FISH in Breast Cancer","volume":"98","author":"Gupta","year":"2018","journal-title":"Lab. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1038\/labinvest.2017.93","article-title":"High Concordance of a Closed-System, RT-QPCR Breast Cancer Assay for HER2 MRNA, Compared to Clinically Determined Immunohistochemistry, Fluorescence in Situ Hybridization, and Quantitative Immunofluorescence","volume":"97","author":"Wasserman","year":"2017","journal-title":"Lab. Investig."},{"key":"ref_20","unstructured":"R Core Team (2022, August 22). R: A Language and Environment for Statistical Computing. Available online: https:\/\/www.R-project.org\/."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Update","volume":"31","author":"Wolff","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/modpathol.2013.103","article-title":"HER2 in Situ Hybridization in Breast Cancer: Clinical Implications of Polysomy 17 and Genetic Heterogeneity","volume":"27","author":"Hanna","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1097\/01.pas.0000165528.78945.95","article-title":"The Influence of Polysomy 17 on HER2 Gene and Protein Expression in Adenocarcinoma of the Breast: A Fluorescent In Situ Hybridization, Immunohistochemical, and Isotopic MRNA In Situ Hybridization Study","volume":"29","author":"Yoder","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","first-page":"163","article-title":"Impact of Polysomy 17 on HER2 Testing of Invasive Breast Cancer Patients","volume":"7","author":"Liu","year":"2013","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/ajcp\/aqz012","article-title":"Impact of the 2018 ASCO\/CAP HER2 Guideline Focused Update","volume":"152","author":"Zynger","year":"2019","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s10549-021-06208-5","article-title":"HER2 Testing in Breast Cancers: Comparison of Assays and Interpretation Using ASCO\/CAP 2013 and 2018 Guidelines","volume":"187","author":"McLemore","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/his.14780","article-title":"Refining the Definition of HER2-Low Class in Invasive Breast Cancer","volume":"81","author":"Atallah","year":"2022","journal-title":"Histopathology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/modpathol.2016.74","article-title":"A Systematic Comparison of Three Commercial Estrogen Receptor Assays in a Single Clinical Outcome Breast Cancer Cohort","volume":"29","author":"Kornaga","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00428-022-03267-x","article-title":"Updates on Breast Biomarkers","volume":"480","author":"Najjar","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/cncr.26431","article-title":"Impact of Low Estrogen\/Progesterone Receptor Expression on Survival Outcomes in Breast Cancers Previously Classified as Triple Negative Breast Cancers","volume":"118","author":"Raghav","year":"2012","journal-title":"Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Robin, X., Turck, N., Hainard, A., Tiberti, N., Lisacek, F., Sanchez, J.-C., and M\u00fcller, M. (2011). PROC: An Open-Source Package for R and S+ to Analyze and Compare ROC Curves. BMC Bioinform., 12.","DOI":"10.1186\/1471-2105-12-77"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1688\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:51:24Z","timestamp":1760122284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/6\/1688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["cancers15061688"],"URL":"https:\/\/doi.org\/10.3390\/cancers15061688","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]}}}